Technologies
Mass spectrometry-based proteomics
An enabling technology
Mass spectrometry-based proteomics is at the core of our drug and biomarker discovery technologies.
- Understanding disease mechanisms and target selection [ProteomeScout™, SignallingScout™]
- Target deconvolution, selectivity profiling and target engagegement [TargetScout™, proteome-wide CETSA® MS]
- Analysis of cellular mode-of-action and resistance formation [SignallingScout™, TargetScout™, proteome-wide CETSA® MS]
- Discovery of molecular and pathway biomarkers for patient stratification and response monitoring [ProteomeScout™, SignallingScout™, Computational Biology]
- Translating biomarkers into a clinical setting [BiomarkerScout™]
- And much more...
Further reading
Schirle, M., Bantscheff, M., and Kuster, B. (2012). Mass Spectrometry-based Proteomics in Preclinical Drug Discovery, Chem Biol 19(1):72-84. [Link]
Aebersold, R., and Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function, Nature 537(7620):347-55. [Link]
Mass spectrometry-based proteomics
A schematic representation of a generic mass spectrometry-based proteomics workflow.